CATALOG PRODUCT FINDER
SEARCH BY KEYWORD:
SEARCH BY SCIENTIFIC FIELD:
EBV LMP2 Products
Select your EBV LMP2 Products including PepMix™ Peptide Pools, MHC-Dextramer, Antigen Peptide or Replitope™ Peptide Arrays!
PepMix™ Peptide Pools
PM-EBV-LMP2
PepMix™ EBV (LMP2)
Pool of 122 peptides derived from a peptide scan through Latent membrane protein 2 (LMP2) of Epstein-Barr virus (HHV4) for T cell assays
Pool of 122 peptides derived from a peptide scan through Latent membrane protein 2 (LMP2) of Epstein-Barr virus (HHV4) for T cell assays

PepMix™ EBV (LMP2)

Application |
Antigen specific T-cell stimulation Immune monitoring T-cell assays T-cell expansion |
Protein Name | Latent membrane protein 2 (LMP2) |
Organism | Epstein-Barr virus (HHV-4) |
Indication / Topic |
Autoimmune disease Burkitt's lymphoma Hodgkin's lymphoma Nasopharyngeal carcinoma |
Number of peptides | 122 |
Further Information:
Amount | 1 vial containing 15 nmol (appr. 25µg) per peptide |
Specifications | Peptide scan (15mers with 11 aa overlap) |
Documentation | Protocol and Datasheet |
Swiss-Prot ID | |
NCBI | YP_401631 |
Sequence |
MGSLEMVPMGAGPPSPGGDPDGYDGGNN SQYPSASGSSGNTPTPPNDEERESNEEP PPPYEDPYWGNGDRHSDYQPLGTQDQSL YLGLQHDGNDGLPPPPYSPRDDSSQHIY EEAGRGSMNPVCLPVIVAPYLFWLAAIA ASCFTASVSTVVTATGLALSLLLLAAVA SSYAAAQRKLLTPVTVLTAVVTFFAICL TWRIEDPPFNSLLFALLAAAGGLQGIYV LVMLVLLILAYRRRWRRLTVCGGIMFLA CVLVLIVDAVLQLSPLLGAVTVVSMTLL LLAFVLWLSSPGGLGTLGAALLTLAAAL ALLASLILGTLNLTTMFLLMLLWTLVVL LICSSCSSCPLSKILLARLFLYALALLL LASALIAGGSILQTNFKSLSSTEFIPNL FCMLLLIVAGILFILAILTEWGSGNRTY GPVFMCLGGLLTMVAGAVWLTVMSNTLL SAWILTAGFLIFLIGFALFGVIRCCRYC CYYCLTLESEERPPTPYRNTV |
Protein Length (aa) | 497 |

Dextramers®
MHC2176
MHC I Dextramer HLA-A*2402 (TYGPVFMCL)
MHC Class I Multimers with dextrane backbone and FITC, APC or PE label. For reproducible detection, enumeration and isolation of antigen-specific T cells
MHC Class I Multimers with dextrane backbone and FITC, APC or PE label. For reproducible detection, enumeration and isolation of antigen-specific T cells

MHC I Dextramer HLA-A*2402 (TYGPVFMCL)

Application |
Immune monitoring Immunohistochemistry T-cell assays |
Protein Name | Selected proteins |
Organism | Epstein-Barr virus (HHV-4) |
Indication / Topic | AIDS (HIV) |
Allele | HLA-A*2402 |
Peptide | TYGPVFMCL |
Antigen | LMP-2 |
Category | EBV |
Further Information:
Amount | 1 vial containing 50 /150 / 500 or 1000 tests |
Specifications | Antigen specific MHC class I multimer with dextran backbone |
Documentation | Protocol and Datasheet |
Protein Length (aa) | 0 |

Antigen Peptides
SP-MHCI-0031
Antigen Peptide EBV LMP2 HLA-A*0201 (CLGGLLTMV)
Antigen Peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.
Antigen Peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

Antigen Peptide EBV LMP2 HLA-A*0201 (CLGGLLTMV)

Sequence | CLGGLLTMV |
Category | Infection |
Allele | HLA-A*0201 |
Species | Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) |
Antigen | EBV LMP2 |
Uniprot ID | P13285 |
Application |
Antigen specific T-cell stimulation T-cell assays T-cell expansion |
Protein Name | Latent membrane protein 2 (LMP2) |
Organism | Epstein-Barr virus (HHV-4) |
Indication / Topic |
Autoimmune disease Burkitt's lymphoma Hodgkin's lymphoma Nasopharyngeal carcinoma |
Number of peptides | 1 |
Further Information:
Amount | 1 vial containing 50 µg peptide |
Specifications | 9mer peptide as TFA salt |
Documentation | Product Datasheet |
Swiss-Prot ID | |
Sequence | H-CLGGLLTMV-OH |
Protein Length (aa) | 0 |

SP-MHCI-0055
Antigen Peptide EBV LMP2 HLA-A*0201 (FLYALALLL)
Antigen Peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.
Antigen Peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

Antigen Peptide EBV LMP2 HLA-A*0201 (FLYALALLL)

Sequence | FLYALALLL |
Category | Infection |
Allele | HLA-A*0201 |
Species | Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) |
Antigen | EBV LMP2 |
Uniprot ID | P13285 |
Application |
Antigen specific T-cell stimulation T-cell assays T-cell expansion |
Protein Name | Latent membrane protein 2 (LMP2) |
Organism | Epstein-Barr virus (HHV-4) |
Indication / Topic |
Autoimmune disease Burkitt's lymphoma Hodgkin's lymphoma Nasopharyngeal carcinoma |
Number of peptides | 1 |
Further Information:
Amount | 1 vial containing 50 µg peptide |
Specifications | 9mer peptide as TFA salt |
Documentation | Product Datasheet |
Swiss-Prot ID | |
Sequence | H-FLYALALLL-OH |
Protein Length (aa) | 0 |

SP-MHCI-0061
Antigen Peptide EBV LMP2 HLA-A*2402 (TYGPVFMCL)
Antigen Peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.
Antigen Peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

Antigen Peptide EBV LMP2 HLA-A*2402 (TYGPVFMCL)

Sequence | TYGPVFMCL |
Category | Infection |
Allele | HLA-A*2402 |
Species | Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) |
Antigen | EBV LMP2 |
Uniprot ID | P13285 |
Application |
Antigen specific T-cell stimulation T-cell assays T-cell expansion |
Protein Name | Latent membrane protein 2 (LMP2) |
Organism | Epstein-Barr virus (HHV-4) |
Indication / Topic |
Autoimmune disease Burkitt's lymphoma Hodgkin's lymphoma Nasopharyngeal carcinoma |
Number of peptides | 1 |
Further Information:
Amount | 1 vial containing 50 µg peptide |
Specifications | 9mer peptide as TFA salt |
Documentation | Product Datasheet |
Swiss-Prot ID | |
Sequence | H-TYGPVFMCL-OH |
Protein Length (aa) | 0 |

SP-MHCI-0103
Antigen Peptide LMP2 HLA-A*2402 (PYLFWLAAI)
Antigen Peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.
Antigen Peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

Antigen Peptide LMP2 HLA-A*2402 (PYLFWLAAI)

Sequence | PYLFWLAAI |
Category | Infection |
Allele | HLA-A*2402 |
Species | Epstein-Barr virus |
Antigen | EBV LMP2 |
Uniprot ID | P13285 |
Application |
Antigen specific T-cell stimulation T-cell assays T-cell expansion |
Protein Name | Latent membrane protein 2 (LMP2) |
Organism | Epstein-Barr virus (HHV-4) |
Indication / Topic |
Autoimmune disease Burkitt's lymphoma Hodgkin's lymphoma Nasopharyngeal carcinoma |
Number of peptides | 1 |
Further Information:
Amount | 1 vial containing 50 µg peptide |
Specifications | 9mer peptide as TFA salt |
Documentation | Product Datasheet |
Swiss-Prot ID | |
Sequence | H-PYLFWLAAI-OH |
Protein Length (aa) | 0 |

RepliTope™ Peptide Microarrays
RT-MW-EBV-LMP2
Multiwell RepliTope™ EBV (LMP2)
Peptide microarray displaying 122 peptides derived from a peptide scan through Latent membrane protein 2 (LMP2) of Epstein-Barr virus (HHV4). Incubation with 20 samples (and one control) in parallel using the Array Slide 24-4 chamber
Peptide microarray displaying 122 peptides derived from a peptide scan through Latent membrane protein 2 (LMP2) of Epstein-Barr virus (HHV4). Incubation with 20 samples (and one control) in parallel using the Array Slide 24-4 chamber

Multiwell RepliTope™ EBV (LMP2)

Application |
Antibody epitope discovery Immune monitoring |
Protein Name | Latent membrane protein 2 (LMP2) |
Organism | Epstein-Barr virus (HHV-4) |
Indication / Topic |
Autoimmune disease Burkitt's lymphoma Hodgkin's lymphoma Nasopharyngeal carcinoma |
Number of peptides | 122 |
Further Information:
Amount | 1 peptide microarray (each peptide is deposited 3x per subarray, 21 subarrays per slide) |
Specifications | Peptide scan (15mers with 11 aa overlap) |
Documentation | Protocol, Datasheet, gal-file and gal-viewer |
Swiss-Prot ID | |
NCBI | YP_401631 |
Sequence |
MGSLEMVPMGAGPPSPGGDPDGYDGGNN SQYPSASGSSGNTPTPPNDEERESNEEP PPPYEDPYWGNGDRHSDYQPLGTQDQSL YLGLQHDGNDGLPPPPYSPRDDSSQHIY EEAGRGSMNPVCLPVIVAPYLFWLAAIA ASCFTASVSTVVTATGLALSLLLLAAVA SSYAAAQRKLLTPVTVLTAVVTFFAICL TWRIEDPPFNSLLFALLAAAGGLQGIYV LVMLVLLILAYRRRWRRLTVCGGIMFLA CVLVLIVDAVLQLSPLLGAVTVVSMTLL LLAFVLWLSSPGGLGTLGAALLTLAAAL ALLASLILGTLNLTTMFLLMLLWTLVVL LICSSCSSCPLSKILLARLFLYALALLL LASALIAGGSILQTNFKSLSSTEFIPNL FCMLLLIVAGILFILAILTEWGSGNRTY GPVFMCLGGLLTMVAGAVWLTVMSNTLL SAWILTAGFLIFLIGFALFGVIRCCRYC CYYCLTLESEERPPTPYRNTV |
Protein Length (aa) | 497 |

RT-EBV-LMP2
RepliTope™ EBV (LMP2)
Peptide microarray displaying 122 peptides derived from a peptide scan through Latent membrane protein 2 (LMP2) of Epstein-Barr virus (HHV4)
Peptide microarray displaying 122 peptides derived from a peptide scan through Latent membrane protein 2 (LMP2) of Epstein-Barr virus (HHV4)

RepliTope™ EBV (LMP2)

Application |
Antibody epitope discovery Immune monitoring |
Protein Name | Latent membrane protein 2 (LMP2) |
Organism | Epstein-Barr virus (HHV-4) |
Indication / Topic |
Autoimmune disease Burkitt's lymphoma Hodgkin's lymphoma Nasopharyngeal carcinoma |
Number of peptides | 122 |
Further Information:
Amount | 1 peptide microarray (each peptide is deposited 3x per subarray, 4 subarrays per slide) + dummy slide and spacers (needed for manual incubation) |
Specifications | Peptide scan (15mers with 11 aa overlap) |
Documentation | Protocol, Datasheet, gal-file and gal-viewer |
Swiss-Prot ID | |
NCBI | YP_401631 |
Sequence |
MGSLEMVPMGAGPPSPGGDPDGYDGGNN SQYPSASGSSGNTPTPPNDEERESNEEP PPPYEDPYWGNGDRHSDYQPLGTQDQSL YLGLQHDGNDGLPPPPYSPRDDSSQHIY EEAGRGSMNPVCLPVIVAPYLFWLAAIA ASCFTASVSTVVTATGLALSLLLLAAVA SSYAAAQRKLLTPVTVLTAVVTFFAICL TWRIEDPPFNSLLFALLAAAGGLQGIYV LVMLVLLILAYRRRWRRLTVCGGIMFLA CVLVLIVDAVLQLSPLLGAVTVVSMTLL LLAFVLWLSSPGGLGTLGAALLTLAAAL ALLASLILGTLNLTTMFLLMLLWTLVVL LICSSCSSCPLSKILLARLFLYALALLL LASALIAGGSILQTNFKSLSSTEFIPNL FCMLLLIVAGILFILAILTEWGSGNRTY GPVFMCLGGLLTMVAGAVWLTVMSNTLL SAWILTAGFLIFLIGFALFGVIRCCRYC CYYCLTLESEERPPTPYRNTV |
Protein Length (aa) | 497 |

News
13 NEW Immunopeptidomics Kits
References for MHC I binding HLA peptides to increase accuracy of neo-epitope identification
(Dec 2020)
Read more
Infectious diseases beyond COVID-19
JPT's peptide formats in the literature
(Oct 2020)
Read more
SARS COV-2 Mass Spec Reference Kit Released!:
SARS-CoV-2 SpikeMix for Mass Spectrometry covers spike, NCAP, VME-1 & ORF9B
(July 2020)
Read more
New! SARS-CoV-2 Epitope Mapping Peptide Sets
Save time and samples and check our new SARS-CoV-2 Epitope Mapping Peptide Sets (EMPS).
(Apr 2020)
Read more
Quality Assurance
All production is performed according to ISO 9001:2015 standards.